Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
MED19 is a component of the Mediator complex, which is a coactivator for DNA-binding factors that activate transcription via RNA polymerase II (Sato et al., 2003 [PubMed 12584197]).[supplied by OMIM, Oct 2008].. Additionally we are shipping MED19 Kits (19) and MED19 Proteins (6) and many more products for this protein.
Showing 10 out of 28 products:
Rat (Rattus) Polyclonal MED19 Primary Antibody for WB - ABIN610993
Hernando, Martin-Vasallo, Ghosh, Ghosh, Swaroop, Coca-Prados: Nucleotide sequence of a cDNA for the beta 2 subunit isoform of Na+,K(+)-ATPase from human retina. in Biochimica et biophysica acta 1994
Show all 3 references for ABIN610993
supports a role for Med19 as a PolII holoenzyme-embedded "co-factor" that acts together with Hox (show MSH2 Antibodies) proteins through their homeodomains in regulated developmental transcription
High expression of Med19 is associated with cisplatin resistance in non-small cell lung cancer cells.
Data show that the expression of Mediator of RNA polymerase II transcription subunit 19 (Med19) was increased in Osteosarcoma (OS) samples from patients compared to normal bone tissues.
High Med19 expression is associated with tongue cancer.
Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone morphogenetic protein 2 (show BMP2 Antibodies).
Med19 is markedly up-regulated in bladder cancer tissues
LCMR1 suppresses apoptosis in lung cancer cells and this effect is associated with multiple apoptosis-related proteins, including p53 (show TP53 Antibodies), Bax (show BAX Antibodies) and Mcl-1 (show MCL1 Antibodies).
High MED19 expression is associated with lung adenocarcinoma cell clone conformation, growth, and metastasis.
Med19 functions in promoting cellular growth and may be a useful therapeutic target in malignant gastric carcinoma
The effect of downregulation of LCMR1 by lentivirus-mediated small hairpin RNA (shRNA) on colorectal cancer cell proliferation and tumorigenesis was explored.
MED19 serves as a novel proliferation regulator that promotes growth of prostate cancer cells.
MED19 is a component of the Mediator complex, which is a coactivator for DNA-binding factors that activate transcription via RNA polymerase II (Sato et al., 2003
mediator complex subunit 19
, mediator of RNA polymerase II transcription, subunit 19 homolog (S. cerevisiae)
, mediator of RNA polymerase II transcription, subunit 19 homolog
, mediator of RNA polymerase II transcription subunit 19
, lung cancer metastasis-related protein 1